{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T11:03:51Z","timestamp":1771844631061,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd001555.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,6,30]],"date-time":"2015-06-30T00:00:00Z","timestamp":1435622400000}}],"reference-count":87,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001555.pub5","type":"journal-article","created":{"date-parts":[[2015,6,30]],"date-time":"2015-06-30T20:17:18Z","timestamp":1435695438000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Treatment for inclusion body myositis"],"prefix":"10.1002","volume":"2015","author":[{"given":"Michael R","family":"Rose","sequence":"first","affiliation":[{"name":"King's College Hospital NHS Foundation Trust; Department of Neurology; Academic Neuroscience Centre Denmark Hill London UK SE5 9RS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Jones","sequence":"additional","affiliation":[{"name":"King's College Hospital NHS Foundation Trust; Department of Neurology; Academic Neuroscience Centre Denmark Hill London UK SE5 9RS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Leong","sequence":"additional","affiliation":[{"name":"NHLI, Imperial College London; ICTEM Builiding; 4th Floor Hammersmith Campus W12 0HS UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maggie C","family":"Walter","sequence":"additional","affiliation":[{"name":"Ludwig-Maximilians-University; Department of Neurology, Friedrich-Baur-Institute, Laboratory for Molecular Myology; Ziemssenstr.1 Munich Germany 80336"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Miller","sequence":"additional","affiliation":[{"name":"Royal Victoria Infirmary; c\/o Department of Neurology, Newcastle upon Tyne Hospitals Trust; Queen Victoria Road Newcastle Upon Tyne UK NE1 4LP"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marinos C","family":"Dalakas","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University; Department of Neurology, Sidney Kimmel Medical College; 901 Walnut Street 4th Floor Philadelphia PA USA 19107"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Brassington","sequence":"additional","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery; MRC Centre for Neuromuscular Diseases; PO Box 114 London UK WC1N 3BG"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Griggs","sequence":"additional","affiliation":[{"name":"University of Rochester; Department of Neurology; 601 Elmwood Avenue Rochester NY USA 14642"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,6,30]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD001555.pub5-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/ana.10121","article-title":"Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo","volume":"51","author":"Badrising","year":"2002","journal-title":"Annals of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD001555.pub5-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001555.pub5-BIB0003|cit3","first-page":"A332","article-title":"Histologic characteristics in repeated muscle biopsies of patients with inclusion body myositis treated in a control trial with high-dose intravenous immunoglobulin and prednisone","volume":"48 Suppl 2","author":"Fujii","year":"1997","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD001555.pub5-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1212\/WNL.56.3.323","article-title":"A controlled study of intravenous immunoglobulin combined with prednisolone in the treatment of IBM","volume":"56","author":"Dalakas","year":"2001","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD001555.pub5-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00005792-199307000-00002","article-title":"The treatment of inclusion body myositis: a retrospective review and a randomised prospective trial of immunosuppressive therapy","volume":"72","author":"Leff","year":"1993","journal-title":"Medicine"},{"issue":"2","key":"10.1002\/14651858.CD001555.pub5-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1212\/01.WNL.0000071852.27182.C7","article-title":"Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study","volume":"61","author":"Lindberg","year":"2003","journal-title":"Neurology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001555.pub5-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"A164","DOI":"10.1136\/annrheumdis-2013-eular.527","article-title":"Safety and tolerability of arimoclomol in patients with sporadic inclusion body myositis: a randomised, double-blind, placebo-controlled, phase IIA proof-of-concept trial","volume":"72","author":"Machado","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD001555.pub5-BIB0008|cit8","unstructured":"Machado P Miller A Herbelin L He J Wang Y McVey AL Arimoclomol study in IBM: [personal communication] Email to P Machado"},{"issue":"9","key":"10.1002\/14651858.CD001555.pub5-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1212\/WNL.57.9.1566","article-title":"Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis","volume":"57","author":"The Muscle Study Group","year":"2001","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD001555.pub5-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1212\/01.WNL.0000134675.98525.79","article-title":"Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis","volume":"63","author":"The Muscle Study Group","year":"2004","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD001555.pub5-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1212\/WNL.58.7.1081","article-title":"A pilot randomized trial of oxandrolone in inclusion body myositis","volume":"58","author":"Rutkove","year":"2002","journal-title":"Neurology"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD001555.pub5-BIB0012|cit12","first-page":"S131","article-title":"High dose intravenous immunoglobulin (IVIG) in the treatment of inclusion body myositis - a double-blind placebo-controlled study","volume":"21","author":"Pongratz","year":"1998","journal-title":"Muscle & Nerve"},{"issue":"1","key":"10.1002\/14651858.CD001555.pub5-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s004150050005","article-title":"High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double blind, placebo-controlled study","volume":"247","author":"Walter","year":"2000","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD001555.pub5-BIB0014|cit14","unstructured":"ACTRN12614000082606 Pilot study of the treatment of patients with sporadic inclusion body myositis with the anaplerotic medication Triheptanoin https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=365625"},{"issue":"8","key":"10.1002\/14651858.CD001555.pub5-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1212\/WNL.44.8.1516","article-title":"Inclusion body myositis: treatment with intravenous immunoglobulin","volume":"44","author":"Amato","year":"1994","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD001555.pub5-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/16501970306110","article-title":"Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction","volume":"35","author":"Arnardottir","year":"2003","journal-title":"Journal of Rehabilitation Medicine"},{"issue":"12","key":"10.1002\/14651858.CD001555.pub5-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/archneur.1982.00510240022006","article-title":"Inclusion body myositis. A corticosteroid-resistant idiopathic inflammatory myopathy","volume":"39","author":"Danon","year":"1982","journal-title":"Archives of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD001555.pub5-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0031-9406(05)60764-X","article-title":"Rehabilitation in myositis: preliminary study","volume":"87","author":"Heikkill\u00e4","year":"2001","journal-title":"Physiotherapy"},{"issue":"4","key":"10.1002\/14651858.CD001555.pub5-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0002-9343(93)90148-I","article-title":"Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy","volume":"94","author":"Joffe","year":"1993","journal-title":"American Journal of Medicine"},{"issue":"1-2","key":"10.1002\/14651858.CD001555.pub5-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.jns.2013.08.007","article-title":"The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study","volume":"334","author":"Kosmidis","year":"2013","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD001555.pub5-BIB0021|cit21","unstructured":"NCT01165008 Anakinra in myositis http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01165008"},{"issue":"2","key":"10.1002\/14651858.CD001555.pub5-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1600-0404.1994.tb01647.x","article-title":"Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases","volume":"89","author":"Lindberg","year":"1994","journal-title":"Acta Neurologica Scandinavica"},{"issue":"1","key":"10.1002\/14651858.CD001555.pub5-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/jnnp.65.1.107","article-title":"Immunoglobulin therapy in inflammatory myopathies","volume":"65","author":"Mastaglia","year":"1998","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD001555.pub5-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0022-510X(01)00478-6","article-title":"Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis","volume":"185","author":"Mowzoon","year":"2001","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD001555.pub5-BIB0025|cit25","unstructured":"NCT00079768 Alemtuzumab to treat sporadic inclusion body myositis http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00079768"},{"key":"10.1002\/14651858.CD001555.pub5-BIB0026|cit26","unstructured":"NCT00917956 Lithium in inclusion body myositis (IBM) (Li-IBM) http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00917956"},{"key":"10.1002\/14651858.CD001555.pub5-BIB0027|cit27","unstructured":"NCT01519349 Follistatin gene transfer to patients with Becker muscular dystrophy and sporadic inclusion body myositis http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01519349"},{"issue":"5","key":"10.1002\/14651858.CD001555.pub5-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1212\/WNL.43.5.876","article-title":"Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin","volume":"43","author":"Soueidan","year":"1993","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001555.pub5-BIB0029|cit29","unstructured":"EUCTR2007-004359-12-IT Simvastatin treatment in inclusion body myositis (IBM) - ND http:\/\/apps.who.int\/trialsearch\/Trial.aspx?TrialID=EUCTR2007-004359-12-IT"},{"key":"10.1002\/14651858.CD001555.pub5-BIB0030|cit30","unstructured":"NCT00001265 Study and treatment of inflammatory muscle diseases http:\/\/www.clinicaltrials.gov\/show\/NCT00001265"},{"key":"10.1002\/14651858.CD001555.pub5-BIB0031|cit31","unstructured":"NCT01423110 Efficacy and safety of bimagrumab\/BYM338 at 52 weeks on physical function, muscle strength, mobility in sIBM patients http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01423110"},{"key":"10.1002\/14651858.CD001555.pub5-BIB0032|cit32","unstructured":"NCT01423110 Efficacy, safety and tolerability of BYM338 in patients with sporadic inclusion body myositis http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01423110"},{"key":"10.1002\/14651858.CD001555.pub5-BIB0033|cit33","unstructured":"NCT02250443 Study of long-term safety, efficacy tolerability of BYM338 in patients with sporadic inclusion body myositis http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02250443"},{"issue":"2","key":"10.1002\/14651858.CD001555.pub5-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1212\/WNL.51.2.598","article-title":"Inclusion body myositis in twins","volume":"51","author":"Amato","year":"1998","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001555.pub5-BIB0035|cit35","article-title":"Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions","volume-title":"Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions","author":"Aronson JK","year":"2006"},{"issue":"9","key":"10.1002\/14651858.CD001555.pub5-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1212\/WNL.55.9.1385","article-title":"Epidemiology of inclusion body myositis in the Netherlands: a nationwide study","volume":"55","author":"Badrising","year":"2000","journal-title":"Neurology"},{"issue":"8","key":"10.1002\/14651858.CD001555.pub5-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1080\/09540120701335238","article-title":"Cost-effectiveness of clinical interventions for AIDS wasting","volume":"19","author":"Beaston-Blaakman","year":"2007","journal-title":"AIDS Care"},{"issue":"6","key":"10.1002\/14651858.CD001555.pub5-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.nmd.2010.03.014","article-title":"International Workshop on Inclusion Body Myositis held at the Institute of Myology, Paris, on 29 May 2009","volume":"20","author":"Benveniste","year":"2010","journal-title":"Neuromuscular Disorders"},{"issue":"Pt 1","key":"10.1002\/14651858.CD001555.pub5-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1093\/brain\/awr213","article-title":"Long-term observational study of sporadic inclusion body myositis","volume":"134","author":"Benveniste","year":"2011","journal-title":"Brain"},{"key":"10.1002\/14651858.CD001555.pub5-BIB0040|cit40","volume-title":"British National Formulary","volume":"68","author":"Joint Formulary Committee","year":"2014"},{"issue":"7","key":"10.1002\/14651858.CD001555.pub5-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD001555.pub5-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11926-013-0329-z","article-title":"Update on treatment of inclusion body myositis","volume":"15","author":"Breithaupt","year":"2013","journal-title":"Current Rheumatology Reports"},{"issue":"2","key":"10.1002\/14651858.CD001555.pub5-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/mus.880060204","article-title":"Clinical investigation in Duchenne dystrophy 2: determination of the \"power\" of therapeutic trials based on the natural history","volume":"6","author":"Brooke","year":"1983","journal-title":"Muscle & Nerve"},{"key":"10.1002\/14651858.CD001555.pub5-BIB0044|cit44","volume-title":"Meyler's Side Effects of Drugs","author":"Chalker","year":"2000"},{"key":"10.1002\/14651858.CD001555.pub5-BIB0045|cit45","unstructured":"The Cochrane Collaboration Cochrane glossary http:\/\/www.cochrane.org\/glossary"},{"issue":"11","key":"10.1002\/14651858.CD001555.pub5-BIB0046|cit46","first-page":"494","article-title":"Polyarticular disability: a functional assessment","volume":"58","author":"Convery","year":"1977","journal-title":"Archives of Physical Medicine and Rehabilitation"},{"issue":"5","key":"10.1002\/14651858.CD001555.pub5-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nmd.2013.02.010","article-title":"Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials","volume":"23","author":"Cortese","year":"2013","journal-title":"Neuromuscular Disorders"},{"issue":"Pt 11","key":"10.1002\/14651858.CD001555.pub5-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1093\/brain\/awr217","article-title":"A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities","volume":"134","author":"Cox","year":"2011","journal-title":"Brain"},{"issue":"27","key":"10.1002\/14651858.CD001555.pub5-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"The New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD001555.pub5-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ana.410370615","article-title":"Common variable immunodeficiency and inclusion body myositis - a distinct myopathy mediated by natural killer cells","volume":"37","author":"Dalakas","year":"1995","journal-title":"Annals of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD001555.pub5-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1017\/S0317167100036684","article-title":"Inclusion body myositis associated with systemic sarcoidosis","volume":"13","author":"Danon","year":"1986","journal-title":"Canadian Journal of Neurological Sciences"},{"key":"10.1002\/14651858.CD001555.pub5-BIB0052|cit52","unstructured":"Department of Health Clinical guidelines for immunoglobulin use: update to second edition http:\/\/www.ivig.nhs.uk\/documents\/dh_129666.pdf (accessed 27 January 2015) 2011"},{"key":"10.1002\/14651858.CD001555.pub5-BIB0053|cit53","volume-title":"Meyler's Side Effects of Drugs","author":"Dukes","year":"2000"},{"issue":"6","key":"10.1002\/14651858.CD001555.pub5-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/ana.410350618","article-title":"Treatment of Guillain-Barre syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study","volume":"35","author":"Dutch Guillain-Barre Syndrome Study Group","year":"1994","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD001555.pub5-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"10","key":"10.1002\/14651858.CD001555.pub5-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/j.1537-2995.2005.00581.x","article-title":"Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review","volume":"45","author":"Fergusson","year":"2005","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD001555.pub5-BIB0057|cit57","unstructured":"McMaster University GRADEpro 2014. www.gradepro.org"},{"issue":"5","key":"10.1002\/14651858.CD001555.pub5-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.410380504","article-title":"Inclusion body myositis and myopathies","volume":"38","author":"Griggs","year":"1995","journal-title":"Annals of Neurology"},{"issue":"10","key":"10.1002\/14651858.CD001555.pub5-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archneur.1985.04060090107026","article-title":"Inclusion body myositis and Sjogren's syndrome","volume":"42","author":"Gutmann","year":"1985","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD001555.pub5-BIB0060|cit60","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD001555.pub5-BIB0061|cit61","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004303.pub2","article-title":"Treatment for swallowing difficulties (dysphagia) in chronic muscle disease","author":"Hill","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD001555.pub5-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.nmd.2009.11.003","article-title":"Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008","volume":"20","author":"Hilton-Jones","year":"2010","journal-title":"Neuromuscular Disorders"},{"issue":"9","key":"10.1002\/14651858.CD001555.pub5-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.bbadis.2009.07.001","article-title":"Hereditary inclusion body myopathy: a decade of progress","volume":"1792","author":"Huizing","year":"2009","journal-title":"Biochimica et Biophysica Acta"},{"issue":"4","key":"10.1002\/14651858.CD001555.pub5-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"473\u20136","DOI":"10.1002\/mus.20958","article-title":"Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity","volume":"37","author":"Jackson","year":"2008","journal-title":"Muscle & Nerve"},{"issue":"2","key":"10.1002\/14651858.CD001555.pub5-BIB0065|cit65","first-page":"306","article-title":"Inclusion body myositis in association with vitamin B12 deficiency and Sj\u00f6gren's syndrome","volume":"19","author":"Khraishi","year":"1992","journal-title":"Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD001555.pub5-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/jnnp.48.3.270","article-title":"Inclusion body myositis: a case with associated collagen vascular disease responding to treatment","volume":"48","author":"Lane","year":"1985","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"10.1002\/14651858.CD001555.pub5-BIB0067|cit67","first-page":"178","article-title":"Inclusion body myositis: association with immunodeficiency","volume":"98 (Suppl)","author":"Lindberg","year":"1990","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD001555.pub5-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1471-2288-7-32","article-title":"Systematic reviews of adverse effects: framework for a structured approach","volume":"7","author":"Loke","year":"2007","journal-title":"BMC Medical Research Methodology"},{"issue":"Pt 3","key":"10.1002\/14651858.CD001555.pub5-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/brain\/112.3.727","article-title":"Inclusion body myositis. Observations in 40 patients","volume":"112","author":"Lotz","year":"1989","journal-title":"Brain"},{"issue":"6","key":"10.1002\/14651858.CD001555.pub5-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"763\u201371","DOI":"10.1097\/01.bor.0000434671.77891.9a","article-title":"Update in inclusion body myositis","volume":"25","author":"Machado","year":"2013","journal-title":"Current Opinion in Rheumatology"},{"issue":"12","key":"10.1002\/14651858.CD001555.pub5-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.jocn.2008.01.011","article-title":"Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis","volume":"15","author":"Needham","year":"2008","journal-title":"Journal of Clinical Neuroscience"},{"issue":"4","key":"10.1002\/14651858.CD001555.pub5-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/00005072-199507000-00012","article-title":"Mitochondrial DNA deletions in muscle fibers in inclusion body myositis","volume":"54","author":"Oldfors","year":"1995","journal-title":"Journal of Neuropathology & Experimental Neurology"},{"issue":"4","key":"10.1002\/14651858.CD001555.pub5-BIB0073|cit73","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004426.pub3","article-title":"Treatment for mitochondrial disorders","author":"Pfeffer","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD001555.pub5-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/(SICI)1097-4598(200006)23:6<970::AID-MUS20>3.0.CO;2-I","article-title":"Prevalence of sporadic inclusion body myositis in Western Australia","volume":"23","author":"Phillips","year":"2000","journal-title":"Muscle & Nerve"},{"key":"10.1002\/14651858.CD001555.pub5-BIB0075|cit75","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"1","key":"10.1002\/14651858.CD001555.pub5-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/archneur.1984.04050130099033","article-title":"Inclusion body myositis and chronic immune thrombocytopenia","volume":"41","author":"Riggs","year":"1984","journal-title":"Archives of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD001555.pub5-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1212\/WNL.57.3.548","article-title":"A prospective natural history study of inclusion body myositis: implications for clinical trials","volume":"57","author":"Rose","year":"2001","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD001555.pub5-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/nan.12149","article-title":"Mitochondrial and inflammatory changes in sporadic inclusion body myositis","volume":"41","author":"Rygiel","year":"2015","journal-title":"Neuropathology and Applied Neurobiology"},{"issue":"6","key":"10.1002\/14651858.CD001555.pub5-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410390615","article-title":"Multiple mitochondrial DNA deletions in sporadic inclusion body myositis: a study of 56 patients","volume":"39","author":"Santorelli","year":"1996","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD001555.pub5-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2042-6410-3-11","article-title":"Sexually dimorphic effects of aging on skeletal muscle protein synthesis","volume":"3","author":"Smith","year":"2012","journal-title":"Biology of Sex Differences"},{"key":"10.1002\/14651858.CD001555.pub5-BIB0081|cit81","first-page":"344","article-title":"Inclusion body myositis in association with rheumatoid arthritis","volume":"21","author":"Soden","year":"1994","journal-title":"Journal of Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD001555.pub5-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2169\/internalmedicine.42.1035","article-title":"Familial inclusion body myositis: a report on two Japanese sisters","volume":"42","author":"Tateyama","year":"2003","journal-title":"Internal Medicine (Tokyo, Japan)"},{"key":"10.1002\/14651858.CD001555.pub5-BIB0083|cit83","first-page":"81\u20134","article-title":"Inclusion body myositis","volume-title":"Diagnostic Criteria for Neuromuscular Disorders","author":"Verschuuren","year":"1997"},{"issue":"7","key":"10.1002\/14651858.CD001555.pub5-BIB0084|cit84","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003907.pub4","article-title":"Strength training and aerobic exercise training for muscle disease","author":"Voet","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD001555.pub5-BIB0085|cit85","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001555","article-title":"Immunotherapy for inclusion body myositis","author":"Rose","year":"1999","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD001555.pub5-BIB0086|cit86","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001555.pub2","article-title":"Treatment for inclusion body myositis","author":"Rose","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD001555.pub5-BIB0087|cit87","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001555.pub4","article-title":"Treatment for inclusion body myositis","author":"Rose","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD001555.pub5\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T11:27:20Z","timestamp":1720265240000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD001555.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Neuromuscular Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,6,30]]},"references-count":87,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001555.pub5","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,30]]}}}